Valuation: Nurix Therapeutics, Inc.

Market Cap 2.69B 2.33B 2.17B 1.99B 3.74B 256B 3.8B 25.49B 10B 128B 10.09B 9.87B 427B P/E 2026 *
16.7x
P/E 2027 * -14.8x
Enterprise Value 1.74B 1.51B 1.41B 1.29B 2.42B 166B 2.46B 16.5B 6.47B 82.95B 6.53B 6.39B 276B EV / Sales 2026 *
2.3x
EV / Sales 2027 * 14.9x
Free-Float
98.67%
Yield 2026 *
-
Yield 2027 * -
1 day+1.37%
1 week+11.46%
Current month+11.50%
1 month+12.23%
3 months+56.66%
6 months+57.33%
Current year+36.43%
1 week 24.54
Extreme 24.54
26.04
1 month 21.23
Extreme 21.23
26.04
Current year 14.01
Extreme 14.01
26.04
1 year 8.2
Extreme 8.195
26.04
3 years 4.22
Extreme 4.22
29.56
5 years 4.22
Extreme 4.22
37.42
10 years 4.22
Extreme 4.22
52.38
Manager TitleAgeSince
Chief Executive Officer 64 2014-09-17
Director of Finance/CFO 60 2016-02-29
Chief Tech/Sci/R&D Officer - 2019-07-31
Director TitleAgeSince
Director/Board Member 64 2014-09-17
Chairman 73 2019-07-31
Chairman 72 2024-05-19
Date Insider Type Main position Quantity % Market Cap.
8/5/26 Fiscal year

Chief Technology Officer

13,068 0.0126%
8/4/26 Sell

Chief Financial Officer

-4,761 0.0046%
8/4/26 Sell

Chief Technology Officer

-4,111 0.0040%
Change 5-day change 1-year change 3-year change Capi.($)
+1.37%+11.46%+163.01%+174.44% 2.69B
+4.21%+25.56%+77.96%+104.49% 70.85B
-0.21%+5.33%+38.61%+68.64% 55.41B
+2.78%+36.87%+23.00%+493.09% 29.43B
-0.30%+13.64%+54.71%+6.07% 24.12B
-0.93%+0.60%-16.89%-12.00% 23.31B
+0.60%+6.71%+47.62%-21.38% 18.37B
+7.26%+14.16%+221.03%+393.89% 16.99B
0.00%+9.69%+31.01%+584.59% 16.1B
-2.05%-3.81%+40.40%+150.40% 13.12B
Average +1.29%+354.73%+68.05%+194.22% 27.04B
Weighted average by Cap. +1.70%+347.40%+56.82%+161.75%

Financials

2026 *2027 *
Net sales 755M 654M 611M 559M 1.05B 72.04B 1.07B 7.17B 2.81B 36.04B 2.84B 2.77B 120B 121M 105M 97.72M 89.31M 168M 11.52B 171M 1.15B 450M 5.76B 453M 444M 19.19B
Net income 368M 319M 298M 272M 513M 35.11B 521M 3.49B 1.37B 17.57B 1.38B 1.35B 58.5B -174M -151M -141M -129M -242M -16.59B -246M -1.65B -647M -8.3B -653M -639M -27.63B
Net Debt -947M -820M -767M -701M -1.32B -90.35B -1.34B -8.99B -3.53B -45.2B -3.56B -3.48B -151B -885M -766M -716M -655M -1.23B -84.44B -1.25B -8.4B -3.3B -42.24B -3.32B -3.25B -141B
Logo Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications.
Employees
317
Date Price Change Volume
26-08-10 US$25.88 +1.37% 898,977
26-08-07 US$25.53 +1.23% 729,851
26-08-06 US$25.22 +0.40% 805,119
26-08-05 US$25.12 +1.74% 1,343,967
26-08-04 US$24.69 +6.33% 1,191,583
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
25.88USD
Average target price
33.50USD
Spread / Average Target
+29.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NRIX Stock